[HTML][HTML] Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension
…, B Tetri, P Thuluvath, D Torres, J Vierling, J Wattacheril… - Gastroenterology, 2020 - Elsevier
Background & Aims Increased levels of galectin 3 have been associated with nonalcoholic
steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (…
steatohepatitis (NASH) and contribute to toxin-induced liver fibrosis in mice. GR-MD-02 (…
Hepatic TLR4 signaling in obese NAFLD
…, G Suarez, J Wattacheril… - American Journal …, 2015 - journals.physiology.org
Nonalcoholic fatty liver disease occurs frequently in the setting of metabolic syndrome, but
the factors leading to nonalcoholic steatohepatitis (NASH) are not fully understood. This study …
the factors leading to nonalcoholic steatohepatitis (NASH) are not fully understood. This study …
[HTML][HTML] rs641738C> T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis
…, NJ Wareham, RM Watanabe, J Wattacheril… - Journal of …, 2021 - Elsevier
Background & Aims A common genetic variant near MBOAT7 (rs641738C>T) has been
previously associated with hepatic fat and advanced histology in NAFLD; however, these …
previously associated with hepatic fat and advanced histology in NAFLD; however, these …
Regulation of adiponectin production by insulin: interactions with tumor necrosis factor-α and interleukin-6
T Hajri, H Tao, J Wattacheril… - American Journal …, 2011 - journals.physiology.org
Obesity is often associated with insulin resistance, low-grade systemic inflammation, and
reduced plasma adiponectin. Inflammation is also increased in adipose tissue, but it is not clear …
reduced plasma adiponectin. Inflammation is also increased in adipose tissue, but it is not clear …
[HTML][HTML] Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
…, C Guy, R Loomba, S Dasarathy, J Wattacheril… - Journal of …, 2020 - Elsevier
Background & Aims Obeticholic acid (OCA), a farnesoid X receptor agonist, increases total
and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. …
and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. …
Lean NAFLD: an underrecognized outlier
J Wattacheril, AJ Sanyal - Current hepatology reports, 2016 - Springer
Nonalcoholic fatty liver disease (NAFLD) is commonly diagnosed in obese or overweight
individuals. However, lean individuals with NAFLD are not rare but represent one significant …
individuals. However, lean individuals with NAFLD are not rare but represent one significant …
Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study
…, N Chalasani, J Wattacheril - Alimentary …, 2019 - Wiley Online Library
… Dr Wattacheril has paid consulting activities with Astra Zeneca and has received research
support from Janssen, Genfit and Intercept, Galectin, Gilead, Zydus, Conatus, Shire. All …
support from Janssen, Genfit and Intercept, Galectin, Gilead, Zydus, Conatus, Shire. All …
A micro-RNA expression signature for human NAFLD progression
Background The spectrum of nonalcoholic fatty liver disease (NAFLD) describes disease
conditions deteriorating from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (…
conditions deteriorating from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (…
Nonalcoholic steatohepatitis (NASH) and hepatic fibrosis: emerging therapies
Nonalcoholic fatty liver disease remains a major cause of liver-related morbidity and mortality
worldwide. It is a complex disease associated with obesity, diabetes, and dyslipidemia but …
worldwide. It is a complex disease associated with obesity, diabetes, and dyslipidemia but …
[HTML][HTML] Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis
Nonalcoholic fatty liver disease (NAFLD) occurs frequently in a setting of obesity, dyslipidemia
and insulin resistance, but the etiology of the disease, particularly the events favoring …
and insulin resistance, but the etiology of the disease, particularly the events favoring …
